Double Digit NASDAQ Stock Winners: KDMN, ATER, GANX
7:34 am Thursday, September 09th, 2021
Following are major stock gainers on Nasdaq in Wednesday’s trading session:
Kadmon Holdings, Inc. (NASDAQ:KDMN) was the active stock gainer on Wednesday and soared 71% to $9.07 after French drugmaker Sanofi said on Wednesday it would buy U.S. biopharmaceutical company Kadmon Holdings for 1.9 billion dollars, one month after announcing the purchase of another US biotech, Translate Bio, for $3.2 billion.
Sanofi said it has offered $9.50 per share in cash for Kadmon, representing a total equity value of approximately $1.9 billion on a fully diluted basis, and that both companies’ boards unanimously approved the transaction.
Rezurock, a treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD), was approved in July by the U.S. Federal Drug Administration (FDA).
Aterian, Inc. (NASDAQ:ATER) stock surged 29.35% to $9.21. Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Mohawk e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company’s platform provides home and kitchen appliances; kitchenware, heating, cooling, and health and beauty products; and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners under the hOmeLabs, Vremi, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, and Spiralizer brands.
Gain Therapeutics, Inc. (NASDAQ:GANX) moved up 20% to $9.49 after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher and Parkinson’s disease. Gain Therapeutics identified the two lead STAR candidates through its proprietary SEE-Tx platform.
The company said the compounds were characterized in assays to potentially help Parkinson’s patients with GBA1 gene mutations as well as patients whose glucocerebrosidase protein is misfolded due to ageing cellular processes.
